These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33631080)

  • 21. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.
    Pouwels KB; Hak E; van der Ende A; Christensen H; van den Dobbelsteen GP; Postma MJ
    Hum Vaccin Immunother; 2013 May; 9(5):1129-38. PubMed ID: 23406816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of routine immunization using meningococcal C conjugate vaccine on invasive meningococcal disease in British Columbia.
    Siu T; Tang W; Dawar M; Patrick DM
    Can J Public Health; 2008; 99(5):380-2. PubMed ID: 19009920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients.
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2005 Aug; 116(2):496-505. PubMed ID: 15995007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
    Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
    Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study.
    Yaesoubi R; Trotter C; Colijn C; Yaesoubi M; Colombini A; Resch S; Kristiansen PA; LaForce FM; Cohen T
    PLoS Med; 2018 Jan; 15(1):e1002495. PubMed ID: 29364884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.
    Halperin SA; Gupta A; Jeanfreau R; Klein NP; Reisinger K; Walter E; Bedell L; Gill C; Dull PM
    Vaccine; 2010 Nov; 28(50):7865-72. PubMed ID: 20943209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile.
    Villena R; Valenzuela MT; Bastías M; Santolaya ME
    Vaccine; 2019 Oct; 37(46):6915-6921. PubMed ID: 31585728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Economic evaluation of the introduction of 4CMenB (Bexsero®) in the national vaccine schedule in Spain].
    Ruiz-Montero R; Epstein D; Guzmán Herrador B; Espín Balbino J
    Gac Sanit; 2020; 34(4):318-325. PubMed ID: 31776044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada.
    Delea TE; Weycker D; Atwood M; Neame D; Alvarez FP; Forget E; Langley JM; Chit A
    PLoS One; 2017; 12(5):e0175721. PubMed ID: 28472165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme.
    Moura Silveira M; McBride AJA; Trotter CL
    Vaccine; 2019 Oct; 37(45):6783-6786. PubMed ID: 31570182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany.
    Christensen H; Irving T; Koch J; Trotter CL; Ultsch B; Weidemann F; Wichmann O; Hellenbrand W
    Vaccine; 2016 Jun; 34(29):3412-9. PubMed ID: 27109566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-utility analysis of the universal pneumococcal vaccination programme for older adults in Norway.
    Nymark LS; Dag Berild J; Lyngstad TM; Askeland Winje B; Frimann Vestrheim D; Aaberge I; Juvet LK; Wolff E
    Hum Vaccin Immunother; 2022 Nov; 18(6):2101333. PubMed ID: 35917277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.
    Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Findlow H; Borrow R; Booy R
    Vaccine; 2018 Jul; 36(29):4375-4382. PubMed ID: 29880243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City.
    Simon MS; Weiss D; Geevarughese A; Kratz MM; Cutler B; Gulick RM; Zucker JR; Varma JK; Schackman BR
    J Acquir Immune Defic Syndr; 2016 Feb; 71(2):146-54. PubMed ID: 26334735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
    Whittles LK; Didelot X; White PJ
    Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.
    Christensen H; Trotter CL; Hickman M; Edmunds WJ
    BMJ; 2014 Oct; 349():g5725. PubMed ID: 25301037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.